Cargando…

Phase II Randomized Controlled Trial of Combined Oral laxatives Medication for BOwel PREParation (COMBO-PREP study)

The combination of different laxatives at reduced volumes may benefit patients by enhancing efficacy for bowel cleansing and increasing tolerability. However, evidence regarding combined preparations is scarce. This study evaluated whether the combined preparations are associated with enhanced effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Min Jung, Hong, Chang Won, Kim, Byung Chang, Park, Sung Chan, Han, Kyung Su, Joo, Jungnam, Oh, Jae Hwan, Sohn, Dae Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998637/
https://www.ncbi.nlm.nih.gov/pubmed/26886637
http://dx.doi.org/10.1097/MD.0000000000002824
_version_ 1782449978008928256
author Kim, Min Jung
Hong, Chang Won
Kim, Byung Chang
Park, Sung Chan
Han, Kyung Su
Joo, Jungnam
Oh, Jae Hwan
Sohn, Dae Kyung
author_facet Kim, Min Jung
Hong, Chang Won
Kim, Byung Chang
Park, Sung Chan
Han, Kyung Su
Joo, Jungnam
Oh, Jae Hwan
Sohn, Dae Kyung
author_sort Kim, Min Jung
collection PubMed
description The combination of different laxatives at reduced volumes may benefit patients by enhancing efficacy for bowel cleansing and increasing tolerability. However, evidence regarding combined preparations is scarce. This study evaluated whether the combined preparations are associated with enhanced efficacy and tolerability. This randomized phase II study had a single-blind, parallel-arm design. Between December 2013 and September 2014, consecutive patients aged between 20 and 65 years and who required diagnostic colonoscopies were considered for inclusion. Patients were randomly allocated into 4 arms: sodium picosulfate and magnesium citrate (PMC) and polyethylene glycol (PEG) with ascorbic acid in a day-prior (PMC-PEG-DP), PMC and oral sodium phosphate (NaP) in a day-prior (PMC-NaP-DP), PMC and PEG with ascorbic acid in a split-dose (PMC-PEG-SD), and PMC and oral NaP in a split-dose (PMC-NaP-SD). Primary endpoint was the Aronchick scale, and Ottawa scale results by colon segment, patients’ adverse gastrointestinal symptoms, and willingness to reuse the same agents were also recorded. Successful bowel preparation was defined as an “excellent” or “good” score on the Aronchick scale. A total of 236 patients were randomized and 229 patients received the planned colonoscopy. The rates of successful bowel preparation in the PMC-PEG-DP, PMC-NaP-DP, PMC-PEG-SD, and PMC-NaP-SD were 82.5%, 64.4%, 100%, and 100%, respectively. Excluding the failed PMC-NaP-DP group, all groups showed satisfactory rates of successful bowel preparation, and the mean Ottawa scores were significantly better in the PMC-PEG-SD and PMC-NaP-SD groups than in the PMC-PEG-DP group (P < 0.0001). The PMC-PEG-DP, PMC-NaP-DP, PMC-PEG-SD, and PMC-NaP-SD groups were similar in terms of rates of adverse gastrointestinal symptoms reported on a 5-point scale (P = 0.40) and willingness to reuse the same combined preparations (P = 0.55). PMC-PEG in a day-prior or split-dose and PMC-NaP in a split-dose were efficient and tolerable bowel preparations for colonoscopy.
format Online
Article
Text
id pubmed-4998637
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-49986372016-09-06 Phase II Randomized Controlled Trial of Combined Oral laxatives Medication for BOwel PREParation (COMBO-PREP study) Kim, Min Jung Hong, Chang Won Kim, Byung Chang Park, Sung Chan Han, Kyung Su Joo, Jungnam Oh, Jae Hwan Sohn, Dae Kyung Medicine (Baltimore) 4500 The combination of different laxatives at reduced volumes may benefit patients by enhancing efficacy for bowel cleansing and increasing tolerability. However, evidence regarding combined preparations is scarce. This study evaluated whether the combined preparations are associated with enhanced efficacy and tolerability. This randomized phase II study had a single-blind, parallel-arm design. Between December 2013 and September 2014, consecutive patients aged between 20 and 65 years and who required diagnostic colonoscopies were considered for inclusion. Patients were randomly allocated into 4 arms: sodium picosulfate and magnesium citrate (PMC) and polyethylene glycol (PEG) with ascorbic acid in a day-prior (PMC-PEG-DP), PMC and oral sodium phosphate (NaP) in a day-prior (PMC-NaP-DP), PMC and PEG with ascorbic acid in a split-dose (PMC-PEG-SD), and PMC and oral NaP in a split-dose (PMC-NaP-SD). Primary endpoint was the Aronchick scale, and Ottawa scale results by colon segment, patients’ adverse gastrointestinal symptoms, and willingness to reuse the same agents were also recorded. Successful bowel preparation was defined as an “excellent” or “good” score on the Aronchick scale. A total of 236 patients were randomized and 229 patients received the planned colonoscopy. The rates of successful bowel preparation in the PMC-PEG-DP, PMC-NaP-DP, PMC-PEG-SD, and PMC-NaP-SD were 82.5%, 64.4%, 100%, and 100%, respectively. Excluding the failed PMC-NaP-DP group, all groups showed satisfactory rates of successful bowel preparation, and the mean Ottawa scores were significantly better in the PMC-PEG-SD and PMC-NaP-SD groups than in the PMC-PEG-DP group (P < 0.0001). The PMC-PEG-DP, PMC-NaP-DP, PMC-PEG-SD, and PMC-NaP-SD groups were similar in terms of rates of adverse gastrointestinal symptoms reported on a 5-point scale (P = 0.40) and willingness to reuse the same combined preparations (P = 0.55). PMC-PEG in a day-prior or split-dose and PMC-NaP in a split-dose were efficient and tolerable bowel preparations for colonoscopy. Wolters Kluwer Health 2016-02-18 /pmc/articles/PMC4998637/ /pubmed/26886637 http://dx.doi.org/10.1097/MD.0000000000002824 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 4500
Kim, Min Jung
Hong, Chang Won
Kim, Byung Chang
Park, Sung Chan
Han, Kyung Su
Joo, Jungnam
Oh, Jae Hwan
Sohn, Dae Kyung
Phase II Randomized Controlled Trial of Combined Oral laxatives Medication for BOwel PREParation (COMBO-PREP study)
title Phase II Randomized Controlled Trial of Combined Oral laxatives Medication for BOwel PREParation (COMBO-PREP study)
title_full Phase II Randomized Controlled Trial of Combined Oral laxatives Medication for BOwel PREParation (COMBO-PREP study)
title_fullStr Phase II Randomized Controlled Trial of Combined Oral laxatives Medication for BOwel PREParation (COMBO-PREP study)
title_full_unstemmed Phase II Randomized Controlled Trial of Combined Oral laxatives Medication for BOwel PREParation (COMBO-PREP study)
title_short Phase II Randomized Controlled Trial of Combined Oral laxatives Medication for BOwel PREParation (COMBO-PREP study)
title_sort phase ii randomized controlled trial of combined oral laxatives medication for bowel preparation (combo-prep study)
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998637/
https://www.ncbi.nlm.nih.gov/pubmed/26886637
http://dx.doi.org/10.1097/MD.0000000000002824
work_keys_str_mv AT kimminjung phaseiirandomizedcontrolledtrialofcombinedorallaxativesmedicationforbowelpreparationcomboprepstudy
AT hongchangwon phaseiirandomizedcontrolledtrialofcombinedorallaxativesmedicationforbowelpreparationcomboprepstudy
AT kimbyungchang phaseiirandomizedcontrolledtrialofcombinedorallaxativesmedicationforbowelpreparationcomboprepstudy
AT parksungchan phaseiirandomizedcontrolledtrialofcombinedorallaxativesmedicationforbowelpreparationcomboprepstudy
AT hankyungsu phaseiirandomizedcontrolledtrialofcombinedorallaxativesmedicationforbowelpreparationcomboprepstudy
AT joojungnam phaseiirandomizedcontrolledtrialofcombinedorallaxativesmedicationforbowelpreparationcomboprepstudy
AT ohjaehwan phaseiirandomizedcontrolledtrialofcombinedorallaxativesmedicationforbowelpreparationcomboprepstudy
AT sohndaekyung phaseiirandomizedcontrolledtrialofcombinedorallaxativesmedicationforbowelpreparationcomboprepstudy